Search by Drug Name or NDC

NDC 00173-0896-01 Blenrep 50 mg/mL Details

Blenrep 50 mg/mL

Blenrep is a INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by GlaxoSmithKline LLC. The primary component is BELANTAMAB MAFODOTIN.

MedlinePlus Drug Summary

Belantamab mafodotin-blmf injection is used to treat multiple myeloma (a type of cancer of the bone marrow) that has returned or has not improved in adults who have received at least 4 other medications. Belantamab mafodotin-blmf is in a class of medications called antibody-drug conjugates. It works by killing cancer cells.

Related Packages: 00173-0896-01
Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Belantamab Mafodotin-blmf Injection

Product Information

NDC	00173-0896
Product ID	0173-0896_eac12010-cb69-47a5-962e-6ae43c8f545c
Associated GPIs	21350515202120
GCN Sequence Number	081362
GCN Sequence Number Description	belantamab mafodotin-blmf VIAL 100 MG INTRAVEN
HIC3	V1K
HIC3 Description	ANTINEOPLASTICS ANTIBODY/ANTIBODY-DRUG COMPLEXES
GCN	48446
HICL Sequence Number	046762
HICL Sequence Number Description	BELANTAMAB MAFODOTIN-BLMF
Brand/Generic	Brand
Proprietary Name	Blenrep
Proprietary Name Suffix	n/a
Non-Proprietary Name	Belantamab
Product Type	HUMAN PRESCRIPTION DRUG
Dosage Form	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Route	INTRAVENOUS
Active Ingredient Strength	50
Active Ingredient Units	mg/mL
Substance Name	BELANTAMAB MAFODOTIN
Labeler Name	GlaxoSmithKline LLC
Pharmaceutical Class	n/a
DEA Schedule	n/a
Marketing Category	BLA
Application Number	BLA761158
Listing Certified Through	n/a

Package

NDC 00173-0896-01 (00173089601)

Pricing Information	N/A
NDC Package Code	0173-0896-01
Billing NDC	00173089601
Package	1 VIAL in 1 CARTON (0173-0896-01) / 2 mL in 1 VIAL
Marketing Start Date	2020-08-05
NDC Exclude Flag	N